214 related articles for article (PubMed ID: 23884215)
1. NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses.
Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A
Hum Vaccin Immunother; 2013 Oct; 9(10):2189-95. PubMed ID: 23884215
[TBL] [Abstract][Full Text] [Related]
2. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.
Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A
Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759
[TBL] [Abstract][Full Text] [Related]
3. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity.
Lladser A; Mougiakakos D; Tufvesson H; Ligtenberg MA; Quest AF; Kiessling R; Ljungberg K
Mol Ther; 2011 Mar; 19(3):594-601. PubMed ID: 21157438
[TBL] [Abstract][Full Text] [Related]
4. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma.
Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos AK; Quest AF; Kiessling R
Cancer Immunol Immunother; 2010 Jan; 59(1):81-92. PubMed ID: 19526360
[TBL] [Abstract][Full Text] [Related]
5. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
6. Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen.
Bråve A; Hallengärd D; Gudmundsdotter L; Stout R; Walters R; Wahren B; Hallermalm K
Vaccine; 2009 Jun; 27(28):3692-6. PubMed ID: 19428161
[TBL] [Abstract][Full Text] [Related]
7. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
8. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
9. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
10. Development of a novel Hsp70-based DNA vaccine as a multifunctional antigen delivery system.
Yamaoka A; Guan X; Takemoto S; Nishikawa M; Takakura Y
J Control Release; 2010 Mar; 142(3):411-5. PubMed ID: 19913062
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
12. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
13. Enhanced CTL response by controlled intracellular trafficking of antigen in dendritic cells following DNA vaccination.
Isaji K; Kawase A; Matono M; Guan X; Nishikawa M; Takakura Y
J Control Release; 2009 May; 135(3):227-33. PubMed ID: 19331843
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccines, electroporation and their applications in cancer treatment.
Lee SH; Danishmalik SN; Sin JI
Hum Vaccin Immunother; 2015; 11(8):1889-900. PubMed ID: 25984993
[TBL] [Abstract][Full Text] [Related]
16. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein.
Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K
Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727
[TBL] [Abstract][Full Text] [Related]
18. Biolistic DNA vaccination against melanoma.
Steitz J; Tüting T
Methods Mol Biol; 2013; 940():317-37. PubMed ID: 23104352
[TBL] [Abstract][Full Text] [Related]
19. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
20. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
